Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis

Introduction Psoriatic arthritis (PsA) affects around 150 000 people in the UK of whom around 50% require treatment with biologics. The most used biologics for PsA target tumour necrosis factor (TNF) or interleukin-17A (IL-17A). About 50% of patients respond to each, but it is not currently possible...

Full description

Bibliographic Details
Main Authors: Iain B McInnes, Stefan Siebert, Paul Bowness, Laura C Coates, Anne Francis, Bruce W Kirkham, Alexander Ooms, Hussein Al-Mossawi, Louise Bennett, Nicole Yager, Duncan Richards, Mimi Bogale, Carl Goodyear, Sylvine Lalnunhlimi, Leonie S Taams, Aysin Tulunay Virlan
Format: Article
Language:English
Published: BMJ Publishing Group 2023-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/9/e078539.full

Similar Items

Similar Items